BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 28924240)

  • 1. 14-3-3ζ binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors.
    Gu Y; Xu K; Torre C; Samur M; Barwick BG; Rupji M; Arora J; Neri P; Kaufman J; Nooka A; Bernal-Mizrachi L; Vertino P; Sun SY; Chen J; Munshi N; Fu H; Kowalski J; Boise LH; Lonial S
    Leukemia; 2018 Mar; 32(3):744-751. PubMed ID: 28924240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma.
    Gu Y; Barwick BG; Shanmugam M; Hofmeister CC; Kaufman J; Nooka A; Gupta V; Dhodapkar M; Boise LH; Lonial S
    Blood Cancer J; 2020 Dec; 10(12):125. PubMed ID: 33318477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosome-Transmitted
    Xu H; Han H; Song S; Yi N; Qian C; Qiu Y; Zhou W; Hong Y; Zhuang W; Li Z; Li B; Zhuang W
    Clin Cancer Res; 2019 Mar; 25(6):1923-1935. PubMed ID: 30610101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
    Tagoug I; Jordheim LP; Herveau S; Matera EL; Huber AL; Chettab K; Manié S; Dumontet C
    Clin Cancer Res; 2013 Jul; 19(13):3556-66. PubMed ID: 23674497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies.
    Hideshima T; Anderson KC
    Semin Hematol; 2012 Jul; 49(3):223-7. PubMed ID: 22726545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
    Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
    Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.
    Zhang XD; Baladandayuthapani V; Lin H; Mulligan G; Li B; Esseltine DW; Qi L; Xu J; Hunziker W; Barlogie B; Usmani SZ; Zhang Q; Crowley J; Hoering A; Shah JJ; Weber DM; Manasanch EE; Thomas SK; Li BZ; Wang HH; Zhang J; Kuiatse I; Tang JL; Wang H; He J; Yang J; Milan E; Cenci S; Ma WC; Wang ZQ; Davis RE; Yang L; Orlowski RZ
    Cancer Cell; 2016 May; 29(5):639-652. PubMed ID: 27132469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.
    Thangavadivel S; Zelle-Rieser C; Olivier A; Postert B; Untergasser G; Kern J; Brunner A; Gunsilius E; Biedermann R; Hajek R; Pour L; Willenbacher W; Greil R; Jöhrer K
    Oncotarget; 2016 Nov; 7(48):78605-78618. PubMed ID: 27732933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple myeloma cells are exceptionally sensitive to heat shock, which overwhelms their proteostasis network and induces apoptosis.
    Sha Z; Goldberg AL
    Proc Natl Acad Sci U S A; 2020 Sep; 117(35):21588-21597. PubMed ID: 32817432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells.
    Auner HW; Moody AM; Ward TH; Kraus M; Milan E; May P; Chaidos A; Driessen C; Cenci S; Dazzi F; Rahemtulla A; Apperley JF; Karadimitris A; Dillon N
    PLoS One; 2013; 8(9):e74415. PubMed ID: 24069311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deacetylation induced nuclear condensation of HP1γ promotes multiple myeloma drug resistance.
    Li X; Wang S; Xie Y; Jiang H; Guo J; Wang Y; Peng Z; Hu M; Wang M; Wang J; Li Q; Wang Y; Liu Z
    Nat Commun; 2023 Mar; 14(1):1290. PubMed ID: 36894562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells.
    Wang X; Mazurkiewicz M; Hillert EK; Olofsson MH; Pierrou S; Hillertz P; Gullbo J; Selvaraju K; Paulus A; Akhtar S; Bossler F; Khan AC; Linder S; D'Arcy P
    Sci Rep; 2016 Jun; 6():26979. PubMed ID: 27264969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells.
    Milan E; Perini T; Resnati M; Orfanelli U; Oliva L; Raimondi A; Cascio P; Bachi A; Marcatti M; Ciceri F; Cenci S
    Autophagy; 2015; 11(7):1161-78. PubMed ID: 26043024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tight Junction Protein 1: New Insights into Proteasome Inhibitor Resistance and Myeloma Pathophysiology.
    Mitsiades CS
    Cancer Cell; 2016 May; 29(5):611-612. PubMed ID: 27165736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomic and functional analyses reveal a dual molecular mechanism underlying arsenic-induced apoptosis in human multiple myeloma cells.
    Ge F; Lu XP; Zeng HL; He QY; Xiong S; Jin L; He QY
    J Proteome Res; 2009 Jun; 8(6):3006-19. PubMed ID: 19364129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma.
    Haertle L; Barrio S; Munawar U; Han S; Zhou X; Simicek M; Vogt C; Truger M; Fernandez RA; Steinhardt M; Weingart J; Snaurova R; Nerreter S; Teufel E; Garitano-Trojaola A; Da Viá M; Ruiz-Heredia Y; Rosenwald A; Bolli N; Hajek R; Raab P; Raab MS; Weinhold N; Haferlach C; Haaf T; Martinez-Lopez J; Einsele H; Rasche L; Kortüm KM
    Clin Cancer Res; 2023 Jan; 29(1):279-288. PubMed ID: 36282272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibitors: introduction.
    Heuck CJ; Shaughnessy JD
    Semin Hematol; 2012 Jul; 49(3):193-5. PubMed ID: 22726541
    [No Abstract]   [Full Text] [Related]  

  • 18. Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
    Gonzalez-Santamarta M; Quinet G; Reyes-Garau D; Sola B; Roué G; Rodriguez MS
    Adv Exp Med Biol; 2020; 1233():153-174. PubMed ID: 32274756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms in multiple myeloma drug resistance.
    Nikesitch N; Ling SC
    J Clin Pathol; 2016 Feb; 69(2):97-101. PubMed ID: 26598624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma.
    Franqui-Machin R; Hao M; Bai H; Gu Z; Zhan X; Habelhah H; Jethava Y; Qiu L; Frech I; Tricot G; Zhan F
    J Clin Invest; 2018 Jul; 128(7):2877-2893. PubMed ID: 29863498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.